Biopharmaceutical Cell Culture Market
Biopharmaceutical Cell Culture Market by Product [Consumables (Media, Sera, Reagents; Accessories), Equipment (Bioreactors, Centrifuges, Filters, Incubators, Freezers)], Type (mAbs, Vaccines, Other), End User (Biopharma, CMOs) - Global Forecast to 2031
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The biopharmaceutical cell culture market is projected to reach USD 24.47 billion by 2031 from USD 12.81 billion in 2026, at a CAGR of 13.8% from 2026 to 2031. Biopharmaceutical cell culture refers to the cultivation of cells in controlled environments to produce therapeutic proteins, monoclonal antibodies, vaccines, and other biological products. These cell culture systems are essential for the development and manufacturing of biopharmaceuticals, supporting applications in drug discovery, process development, and large-scale commercial production.
KEY TAKEAWAYS
-
BY REGIONThe Asia Pacific is projected to register the highest growth rate of 13.7% in the biopharmaceutical cell culture market during the forecast period.
-
BY PRODUCTBy product, the consumables segment is projected to register the highest CAGR of 13.1% in the global biopharmaceutical cell culture market during the forecast period.
-
BY TYPEBy type, the vaccine production segment is projected to register the highest CAGR of 13.6% during the forecast period.
-
COMPETITIVE LANDSCAPE - KEY PLAYERSThermo Fisher Scientific, Danaher, and Merck were identified as star players in the global biopharmaceutical cell culture market, given their strong market share and extensive product footprint.
-
COMPETITIVE LANDSCAPE - STARTUPSCaisson Labs and Solida Biotech have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The biopharmaceutical cell culture market is expanding rapidly, driven by increasing demand for monoclonal antibodies, vaccines, and biosimilars, as well as the growing adoption of single-use technologies and advanced bioprocessing systems. The rising investment in biopharmaceutical manufacturing capacity, expanding contract development and manufacturing organizations, and increasing focus on cell-based research and regenerative medicine are further accelerating demand for high-performance cell culture products and systems.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The biopharmaceutical cell culture market is currently experiencing a phase of innovation and rapid adoption. Biopharmaceutical companies, contract manufacturers, and research institutions in North America, Europe, and the Asia Pacific are witnessing advancements in cell culture technology and bioprocessing capabilities. This progress aligns with emerging trends in precision medicine, cell & gene therapies, and next-generation biologics. The use of single-use bioreactors, advanced cell culture media, and automated bioprocessing platforms is increasing among biopharmaceutical manufacturers and research centers. These technologies facilitate scalable production of therapeutic proteins and antibodies, reduce contamination risks, shorten turnaround times, and align with flexible manufacturing and cost-efficient production approaches. Governments and regulatory bodies are encouraging local biomanufacturing, the development of biosimilars, and public-private research and development programs. These initiatives help shorten approval timelines and promote the adoption of validated, automation-friendly cell culture platforms tailored to the needs of regional biopharmaceutical production.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rapid expansion of biopharmaceutical manufacturing infrastructure and increasing healthcare expenditure
-
Growing demand for monoclonal antibodies and cell-based vaccines
Level
-
High cost of cell biology research and bioprocessing equipment
Level
-
Expanding demand for single-use technologies and advanced cell culture systems
Level
-
Plastic consumables disposal
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rapid expansion of biopharmaceutical manufacturing infrastructure and increasing healthcare expenditure
The rapid expansion of biopharmaceutical manufacturing infrastructure globally, along with rising healthcare expenditure, is supporting greater adoption of cell culture technologies. Governments and private players are investing in biomanufacturing facilities, contract manufacturing organizations, and advanced bioprocessing capabilities, which is increasing the use of cell culture products in therapeutic protein production, vaccine manufacturing, and biologics development.
Restraint: High cost of cell biology research and bioprocessing equipment
The high cost of cell biology research and bioprocessing equipment restricts the adoption of advanced cell culture systems, especially in developing economies. Differences in capital availability, pricing pressures, and infrastructure readiness create challenges for manufacturers and research institutions trying to implement high-value cell culture technologies across the region.
Opportunity: Expanding demand for single-use technologies and advanced cell culture systems
The growing demand for single-use technologies and advanced cell culture systems presents significant growth opportunities globally. These technologies are increasingly utilized in flexible biomanufacturing, rapid process development, and contamination-free production environments, aligning well with the focus on cost-effective and scalable biopharmaceutical manufacturing.
Challenge: Plastic consumables disposal
Plastic consumables disposal is a growing challenge in the global biopharmaceutical cell culture market because large volumes of single-use bags, tubing, filters, and liners are generated in upstream manufacturing. After use, these materials often need special collection, decontamination, and treatment. As a result, much of this waste is still sent for incineration or disposal, which raises waste-handling costs and adds to sustainability pressure for biopharma manufacturers. This challenge is becoming more important as companies expand single-use cell culture operations and, at the same time, face stronger ESG and circularity expectations from customers, regulators, and investors.
BIOPHARMACEUTICAL CELL CULTURE MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Sartorius partnered with LFB BIOMANUFACTURING to provide cell line development services and cell culture media for therapeutic protein manufacturing. LFB, as the end user biomanufacturer/CDMO, uses Sartorius’ upstream capabilities together with its own manufacturing platform to support biologics production. | Helps speed up protein therapy development, improves scale-up readiness, and gives a more integrated path from cell line development to manufacturing. |
 |
Sartorius entered a strategic cooperation with Mabion, a biologics CDMO, where Sartorius provides proprietary cell culture media, cell line development, and upstream process optimization to support Mabion’s biopharmaceutical development and large-scale manufacturing activities. | Supports smoother transfer from lab-scale to commercial-scale production, reduces development complexity, and strengthens biologics manufacturing efficiency for Mabion’s customers. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The global biopharmaceutical cell culture market is a collaborative ecosystem where equipment suppliers, consumables manufacturers, biotech firms, contract organizations, and biopharmaceutical companies work together to develop and implement cell culture technologies in the biopharmaceutical sector. Companies supply a variety of cell culture products, including media, sera, reagents, bioreactors, and single-use systems. Contract research organizations, contract development and manufacturing organizations, and research institutions support the preclinical and clinical development stages, as well as the scale-up process for biopharmaceutical production. Ultimately, biopharmaceutical companies and healthcare institutions utilize the developed cell culture technologies, benefiting from supportive regulations and government incentives.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Biopharmaceutical Cell Culture Market, by Product
Consumables dominated the market in 2025, with cell culture media, sera, and reagents being the backbone of most biopharmaceutical production processes used daily in manufacturing facilities and research laboratories. This is due to their essential role in cell growth, productivity, and process consistency, making them preferred for monoclonal antibody production and vaccine manufacturing.
Biopharmaceutical Cell Culture Market, by Type
Monoclonal antibodies represented the largest type segment of the global biopharmaceutical cell culture market in 2025. Their dominance is mainly linked to the high manufacturing volume of mAbs across oncology, autoimmune, and other chronic disease therapies, which drives sustained demand for mammalian cell culture media, feeds, bioreactors, and other upstream consumables. The segment also benefits from continued expansion in biologics manufacturing capacity, including large-scale facilities dedicated to monoclonal antibody production.
REGION
Asia Pacific to be fastest-growing region in market during forecast period
The Asia Pacific is projected to be the fastest-growing region in the global biopharmaceutical cell culture market because the region is seeing strong expansion in biologics manufacturing capacity, along with rising investment in local bioprocessing infrastructure and technical support. Countries such as South Korea, Singapore, China, and India are strengthening their position in biologics production, which is increasing demand for cell culture media, bioreactors, and other upstream manufacturing inputs.
BIOPHARMACEUTICAL CELL CULTURE MARKET: COMPANY EVALUATION MATRIX
Thermo Fisher Scientific, recognized as a key player in the global biopharmaceutical cell culture market, offers a broad portfolio of Gibco cell culture media, feeds, sera, reagents, and single-use bioprocessing solutions used in biologics manufacturing. The company has a strong position across upstream bioproduction, supported by its global manufacturing network and technical capabilities serving monoclonal antibody, vaccine, and other biologics producers. Thermo Fisher is also expanding its biopharma support footprint through investments in bioprocess design and manufacturing capabilities, strengthening its role as a strategic supplier to biopharmaceutical manufacturers globally.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 11.63 Billion |
| Market Forecast in 2031 (Value) | USD 24.47 Billion |
| Growth Rate | CAGR of 13.8% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
WHAT IS IN IT FOR YOU: BIOPHARMACEUTICAL CELL CULTURE MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Understanding demand patterns for cell culture products across North American biopharmaceutical facilities | Assessed cell culture product usage trends across the US, highlighting differences in adoption of media, sera, reagents, and bioreactor systems across monoclonal antibody production, vaccine manufacturing, and biosimilar development applications. | Helps clients align product portfolios with country-specific demand drivers, regulatory maturity, and production volumes. |
| Identifying local manufacturing and sourcing opportunities | Mapped cell culture suppliers across some parts of Asia Pacific, contract manufacturing organizations, and biopharmaceutical companies, with insights into media formulation, bioreactor manufacturing, consumables production, and bioprocessing raw material supply. | Supports localization strategies, reduces supply-chain risk, lowers production costs, and improves speed-to-market. |
RECENT DEVELOPMENTS
- March 2024 : Sartorius partnered with LFB BIOMANUFACTURING, a recombinant protein CDMO, to provide high-performing cell lines and cell culture media as part of an end-to-end biologics development and manufacturing solution. Under the agreement, LFB outsourced cell line development to Sartorius, while LFB handled scale-up and clinical manufacturing for biopharma customers.
- April 2023 : Cytiva launched X-platform bioreactors to simplify single-use upstream bioprocessing operations. The X-platform bioreactors can be used to manufacture monoclonal antibodies, cell & gene therapies, and viral vectors. The bioreactors are customizable and scalable and are expected to increase productivity in process development and manufacturing.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global biopharmaceutical cell culture market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the biopharmaceutical cell culture market. The secondary sources used for this study include World Health Organization (WHO), Food and Drug Administration, American Society for Cell Biology (ASCB), National Institutes of Health (NIH), International Society for Cell & Gene Therapy (ISCT), American Society for Gene and Cell Therapy (ASGCT), Centers of Disease Control and Prevention (CDC), International Serum Industry Association (ISIA), Pharmaceutical Research and Manufacturers of America (PhRMA), International Society for Vaccines (ISV), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the Society for In Vitro Biology (SIVB), Japan Agency for Medical Research and Development, European Federation of Pharmaceutical Industries and Associations (EFPIA), American Type Culture Collection (ATCC), and the Alliance for Regenerative Medicine (ARM); corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
After acquiring foundational knowledge about the global biopharmaceutical cell culture market through secondary research, extensive primary research was conducted. Multiple interviews were held with market experts from the demand side, including representatives from pharmaceutical and biopharmaceutical companies, hospitals & diagnostic laboratories, research & academic institutes, and CROs. Additionally, experts from the supply side were interviewed, including C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
These interviews spanned five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while the remaining 30% were with demand-side participants. The primary data was collected through various methods, including questionnaires, emails, online surveys, personal interviews, and telephone interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the biopharmaceutical cell culture market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Bottom-up Approach and Top-down Approach
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Biopharmaceutical cell culture refers to removing cells from an animal or plant and their subsequent growth in an artificial environment under controlled conditions. It is a process of growing cells outside their natural environment, typically in a laboratory setting. This technique allows researchers to study cells in a controlled environment, providing insights into their behavior, growth, metabolism, and response to various stimuli.
Stakeholders
- Biopharmaceutical Cell Culture Equipment and Reagents Manufacturers
- Analytical and Life Science Instrumentation Companies
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Life Science Companies
- Venture Capitalists and Investors
- Government Organizations
- Private Research Firms
- Contract Research Organizations (CROs)
- Hospitals and Diagnostic Laboratories
- Cell Banks
Report Objectives
- To define, describe, and forecast the global biopharmaceutical cell culture market based on the product, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro-markets with respect to individual growth trends, future prospects, and contributions to the overall biopharmaceutical cell culture market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, and R&D activities in the biopharmaceutical cell culture market
- To benchmark players within the biopharmaceutical cell culture market using the ‘Company Evaluation Matrix’ framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Biopharmaceutical Cell Culture Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Still Researching the
Biopharmaceutical Cell Culture Ecosystem?
See the competitors, opportunity evaluation, and growth signals shaping it - Instantly!
Generate 15+ consulting-grade strategic intelligence outputs - from competitor analysis to board-ready strategy decks, tailored to your Biopharmaceutical Cell Culture growth question.
Growth opportunities and latent adjacency in Biopharmaceutical Cell Culture Market